Allworth Financial’s Vor Biopharma VOR Stock Holding History

Allworth Financial’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$185	Sell	10 -63	-86%	-$953	﹤0.01%	4970
2026 Q1	$1.3K	Buy	73 +70	+2,333%	+$987	﹤0.01%	4493
2025 Q4	$40	Hold	3	–	–	﹤0.01%	4862
2025 Q3	$147	Hold	3	–	–	﹤0.01%	4632
2025 Q2	$98	Buy	+3	New	+$27	﹤0.01%	4399

Other funds holding VOR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Allworth Financial's VOR Position: Q2 2026 in Review

Allworth Financial reduced its Vor Biopharma (VOR) stake by 86% in Q2 2026, selling an estimated $953 and leaving 10 shares worth $185. The position accounts for ﹤0.01% of the portfolio, ranked #4970.

Allworth Financial first reported a position in VOR in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.3K in Q1 2026. 43 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Allworth Financial held 10 shares of Vor Biopharma worth $185 as of Q2 2026.
Allworth Financial sold 63 Vor Biopharma shares in Q2 2026, an estimated $953.
Vor Biopharma made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4970 holding.
Allworth Financial first reported a position in Vor Biopharma in Q2 2025 and has held it in 5 quarters since.
Allworth Financial's Vor Biopharma position peaked at $1.3K in Q1 2026.
43 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.